Literature DB >> 6815046

Valproate-induced hepatic steatogenesis in rats.

J H Lewis, H J Zimmerman, C T Garrett, E Rosenberg.   

Abstract

The administration of high-dose valproic acid (VPA) (750 mg per kg) consistently produced significant microvesicular steatosis in mature Sprague-Dawley rats after 48 hr. Similar changes occurred in animals pretreated with phenobarbital which received a lower dose of VPA (350 mg per kg), but no steatosis was seen in animals treated with the low-dose VPA alone. The steatogenic effect of VPA is most likely mediated by a toxic metabolite. It can also be speculated that phenobarbital, by enhancing the inducing effects of the hepatic mixed-function oxidase system, may lead to increased conversion of VPA to a toxic metabolite. Young and weanling rats appeared to be resistant to the steatogenic effects of VPA. Reproduction of microvesicular steatosis in this experimental; model may permit exploration of factors that enhance or inhibit VPA-induced hepatic injury.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6815046     DOI: 10.1002/hep.1840020622

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate.

Authors:  N Bach; S N Thung; F Schaffner; H Tobias
Journal:  Dig Dis Sci       Date:  1989-08       Impact factor: 3.199

Review 2.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 3.  Hepatotoxicity to sodium valproate: a review.

Authors:  P R Powell-Jackson; J M Tredger; R Williams
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

4.  Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.

Authors:  Hiren R Modi; Mireille Basselin; Ameer Y Taha; Lei O Li; Rosalind A Coleman; Meir Bialer; Stanley I Rapoport
Journal:  Biochim Biophys Acta       Date:  2013-01-23

Review 5.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

Review 6.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 7.  Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.

Authors:  J R Stephens; R H Levy
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 8.  Metabolism of valproate to hepatotoxic intermediates.

Authors:  T A Baillie
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 9.  Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.

Authors:  W Löscher
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 10.  Influence of co-medication on the metabolism of valproate.

Authors:  F Pisani
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.